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Abstract
Background: Command hallucinations are among the most distressing, high risk and treatment resistant
symptoms for people with psychosis; however, currently, there are no evidence-based treatment options available
for this group. A cognitive therapy grounded in the principles of the Social Rank Theory, is being evaluated in
terms of its effectiveness in reducing harmful compliance with command hallucinations.
Methods/Design: This is a single blind, intention-to-treat, multi-centre, randomized controlled trial comparing
Cognitive Therapy for Command Hallucinations + Treatment as Usual with Treatment as Usual alone. Eligible
participants have to fulfil the following inclusion criteria: i) ≥16 years; ii) ICD-10 diagnosis of schizophrenia or
related disorder; iii) command hallucinations for at least 6 months leading to risk of harm to self or others.
Following the completion of baseline assessments, eligible participants will be randomly allocated to either the
Cognitive Therapy for Command Hallucinations + Treatment as Usual group or the Treatment as Usual group.
Outcome will be assessed at 9 and 18 months post randomization with assessors blind to treatment allocation. The
primary outcome is compliance behaviour and secondary outcomes include beliefs about voices’ power, distress,
psychotic symptoms together with a health economic evaluation. Qualitative interviews with services users will
explore the acceptability of Cognitive Therapy for Command Hallucinations.
Discussion: Cognitive behaviour therapy is recommended for people with psychosis; however, its focus and
evaluation has primarily revolved around the reduction of psychotic symptoms. In this trial, however, the focus of
the cognitive behavioural intervention is on individuals’ appraisals, behaviour and affect and not necessarily
symptoms; this is also reflected in the outcome measures used. If successful, the results will mark a significant
breakthrough in the evidence base for service users and clinicians and will provide a treatment option for this
group where none currently exist. The trial will open the way for further breakthrough work with the ‘high risk’
population of individuals with psychosis, which we would intend to pursue.
Trial registration: ISRCTN: ISRCTN62304114
Background
Schizophrenia affects 0.8% of the UK population, usually
starts in early adult life and leads to persistent disability
in most cases [1]. It carries a high risk of suicide (8%)
and deliberate self-harm [2] and, on a population basis,
people with schizophrenia are more likely to perpetrate
acts of aggression than their peers [3]. While drug treat-
ment has improved, approaching fifty per cent will con-
tinue to experience treatment resistant symptoms [4] or
symptoms arising from refusal to adhere with drug
regimes [5]. Auditory hallucinations rank among the
most prominent of the treatment resistant symptoms [6]
and the most distressing and high risk of all are com-
mand hallucinations [6,7]. Command hallucinations are
very prevalent in people who experience schizophrenia.
A recent review by Shawyer et al [7] reported a median
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89% in a sample of adult psychiatric patients. Further-
more, it was reported that 48% of command hallucina-
tions stipulate harmful or dangerous actions [7] rising to
69% among patients in medium secure units [8]. This
rate was significantly higher in the forensic population
with 83% of voice hearers experiencing command hallu-
cinations with criminal content [7].
However, the link between command hallucinations
and harm to self or others is not straightforward. In the
Macarthur study [9,10] no association was reported
between the presence of delusions or command halluci-
nations and violence (GBH, assault and threats with a
weapon). Thoughts about violence, on the other hand,
were a strong predictor of violence six months later. A
recent secondary analysis of the Macarthur study by
Rogers [11,12] found that an additional significant pre-
dictor of aggression is beliefs about having to “obey“ the
voice. Thus, it appears to be the content of the indivi-
dual’st h i n k i n ga n dh o wt h i sr e f l e c t st h ed y n a m i c so f
the individual’s relationship with their supposed perse-
cutor who is commanding that is found to be predictive
of harm to self and others in command hallucinations
[13,14]. This was further confirmed by Trower et al [14]
who found that it is the content of the voice and the
individual’s relationship with the personified voice that
predicts compliance, distress and depression. These
findings are in accordance with the social rank theory
which suggests that individuals in subordinate positions
will comply with the demands of those more dominant,
or appease when compliance is risky or dangerous, but
escape is impossible. In command hallucinations, the
greater the power differential between the voice and the
voice hearer, the greater the possibility of complying
with “benevolent” voices or resisting but appeasing
“malevolent” voices [13,14]. From the voice hearer’s
point of view, non-compliance risks harmful action from
the voice (e.g. death to self or family), placing the indivi-
dual in a dilemma often resolved by harmful appease-
ment or compliance. These findings have been
independently replicated by Fox et al [15] comparing
people who have complied with their voices vs. those
who have resisted compliance. The former perceived
their commanding voice to be more powerful and them-
selves to be inferior, hence motivating the need to sub-
mit to the voice and comply with its commands.
Nevertheless, predicting who,a n dwhen individuals
will act on their voices has proven difficult in spite of
these epidemiological data; also, why people respond to
their voices in the above varying ways (e.g. complying,
appeasing) is something that warrants exploring. The
aim of our MRC COMMAND trial is to answer these
questions while at the same time evaluate the efficacy of
a cognitive behavioural therapy (CTCH) in reducing
harmful compliance with command hallucinations.
Cognitive behavioural therapy (CBT) is a psychological
therapy originally developed for the management of
emotional disorders like depression and anxiety disor-
ders. The link between thinking and emotion/behaviour
lies at the heart of this therapy such that emotional and
behavioural responses are principally influenced by cog-
nitive appraisals. CBT was further developed for the
treatment of severe mental health problems like psycho-
sis and has been thoroughly validated through large-
scale pragmatic trials using primarily standard psychosis
outcomes (e.g. Positive and Negative Symptom Scale)
[16] (Birchwood & Trower, 2006). CBT is now recom-
mended by the National Institute for Clinical Excellence
[17] (2002) “to reduce psychotic symptoms, increase
insight and promote medication adherence”.
Hypotheses
The primary hypothesis to be tested is whether in
patients with command hallucinations who have acted
on their voices and are therefore at high risk of doing
so again, cognitive therapy for command hallucinations
(CTCH) will prevent further harmful compliance beha-
viour, and thereby reduce risk.
Secondary hypotheses predict that:
(a) any reduction in compliance will be mediated by
reduced conviction in the perceived power of the perse-
cuting voice,
(b) CTCH will reduce delusional distress and depres-
sion, but
(c) we are not predicting any change in the frequency
or topography of voices per se.
Method/Design
The trial is funded by the Medical Research Council and
has received ethical approval from the West Midlands
Research Ethics Committee.
This is a single (rater) blind, prospective, pragmatic
randomised controlled trial, using intention to treat
comparing CTCH + TAU with TAU alone. The trial is
recruiting participants with schizophrenia and schizoaf-
fective disorders, with treatment resistant auditory hallu-
cinations from inpatient wards and community mental
health teams in Birmingham & Leicester, London and
Manchester. Recruitment to the trial began in February
2008 and was completed in July 2010. Follow-up assess-
ments began in November 2008 and will be completed
in January 2012.
The intervention
CTCH is designed to weaken and change beliefs about
voices’ power, thus enabling the individual to break free
of the need to comply or appease and thereby reduce
harmful compliance behaviour and distress. CTCH uses
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conviction in four beliefs linked to the construct of
voice power: that the voice has absolute power and
control; that the individual must comply or appease or
be severely punished; the identity of the voice (e.g. the
Devil) and the meaning attached to the voice experience
(e.g. the individual is being punished for past bad
behaviour).
The CTCH protocol is described in Byrne et al [18],
and in our casebook manual [19]. While the interven-
tion is protocol based, it recognises individual differ-
ences in voice content, beliefs about voices and
compliance. CTCH differs from previous and generic
types and models of CBT for psychosis. First, it is
informed by a well validated theoretical framework that
predicts individuals’ compliance with voices and the
associated distress rather than the presence of symptoms
per se. Second, it adheres to a staged process informed
by the explanatory model. Third, the model proposes a
single variable that is the target of therapy and also the
hypothesised mediator: the power differential between
voice and voice hearer.
The intervention is delivered in each centre by accre-
dited cognitive therapists and clinical psychologists
supervised by a lead clinician with expertise in CBT for
psychosis. Group supervision across sites via videocon-
ference was also conducted once a fortnight in order to
monitor compliance to protocol and minimise centre
differences in implementation. Adherence to protocol is
monitored using our adapted version of the Cognitive
Therapy Checklist [20].
CTCH is administered over a maximum period of 9
months. This includes a therapeutic window of approxi-
mately 25 sessions.
Treatment as Usual (TAU)
Treatment as Usual (TAU) is provided by Community
Mental Health or Assertive Outreach Teams, or inpati-
ent ward teams. TAU including neuroleptic medication
will be documented in line with the trial protocol
derived from out pilot study [14].
Inclusion and exclusion criteria
Eligible participants fulfil the following criteria: i) ICD-
10 schizophrenia, schizoaffective (F20,22,23,25,28,29:
WHO, 1999) [21], or ICD-10 diagnosis of Mood disor-
ders (F32) under care of the clinical team (ii) age ≥16,
(iii) history of command hallucinations of at least 6
months with history of harm to self, others or major
social transgressions as a result of the commands; or
harmful command hallucinations where the individual is
distressed and appeasing the powerful voice. Exclusion
criteria include: organic impairment or addictive
disorder considered to be the primary diagnosis and
insufficient command of the English language.
Recruitment and randomisation
Eligible participants are identified by Clinical Studies
Officers from the UK Mental Health Research Net-
work who review the medical records looking for i)
history of auditory hallucinations and ii) evidence of
risky, aggressive and violent behaviour. A screening
interview is conducted in order to confirm eligibility
for the trial. Following the screening interview, eligible
participants are invited to take part and asked to pro-
vide informed consent. Once informed consent has
been obtained, trained researchers administer a battery
of assessments and upon completion of the assess-
ments, participants are randomly allocated either to
the CTCH+TAU group or the TAU group (i.e. the
Control group). Randomisation is conducted by
OpenCDMS (http://www.opencdms.org) an online sys-
tem managed by the University of Manchester in
order to ensure concealment of group allocation. Ran-
domisation was stratified by Centre using randomised-
permuted blocks with a randomly-varying block size.
Group allocation is revealed to the service user, clini-
cian, trial manager, trial administrator and the trial
therapists.
Measures
Behavioural responses to voices
The level of compliance/resistance with each command
is assessed using the Voice Compliance Scale (VCS)
[13,14] after: a) conducting a thorough interview using
the Cognitive Assessment of Voices schedule in order to
obtain a detailed description of all voices as well as
emotional and behavioural responses towards these
voices b) interviewing and using information from other
informants (carers, care-coordinator). Information col-
lected by all these sources is collated in the form of a
vignette and each behaviour is then classified as: neither
appeasement nor compliant (1), symbolic appeasement,
i.e. compliant with innocuous and/or harmless com-
mands (2), actual appeasement i.e. preparatory acts or
gestures (3), partial compliance with at least one severe
command (4), full compliance with at least one severe
command (5). These behaviours will be independently
rated by the trial manager to ensure reliability of ratings.
Beliefs about voices
The Beliefs about Voices Questionnaire (BAVQ-R) [22]
is used to assess key beliefs about the voices including
benevolence/malevolence as well as emotional and
behavioural reactions towards the voices. The scale has
good test-retest (0.89) internal reliability (Cronbach’s
alpha = 0.85).
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The Voice Power Differential Scale (VPD) [23,24] is
used to measure the perceived power differential
between voice and voice hearer and includes the follow-
ing constructs: strength, confidence, respect, ability to
inflict harm, superiority and knowledge. This scale has
good internal reliability (Cronbach’sa l p h a=0 . 8 5 )w i t h
one week re-test reliability (r = 0.82).
Omniscience
The Personal Knowledge questionnaire/Omniscience
scale [23] measures the voice hearer’s beliefs about the
voice’s knowledge regarding personal information (e.g.
“The voice knows everything about me and my past”).
Distress
Distress associated with voices is assessed using the
Psychotic Symptoms Rating [25] Scales and specifically
the section about auditory hallucinations (AH). The
scale benefits from excellent psychometric properties
with inter-rater reliability for the AH section ranging
between 0.78-1.0.
Depression
The Calgary Depression Rating Scale for Schizophrenia
[26] is a nine item observer rated measure specifically
designed for schizophrenia, minimizing contamination
by negative symptoms and the extrapyramidal side
effects of neuroleptics. It is strongly correlated with the
BDI [27] (r = 0.91) and is responsive to change in psy-
chosis [14]. Recent studies have also supported the use
of CDSS in healthy and non-psychotic populations [28].
Psychotic Symptoms
The Positive and Negative Syndrome Scale (PANSS) [29]
includes scales of positive symptoms, negative symptoms
and general psychopathology and is used widely in
schizophrenia research.
Hopelessness & Suicidal Ideation
The Beck Hopelessness Scale [30] is used to assess three
aspects of hopelessness: feelings about the future, loss of
motivation and expectations. The Beck Scale for Suicidal
Ideation [31] allows for a thorough examination of
suicidal intent.
Childhood Trauma
The Childhood Trauma Questionnaire [32] is a 28-item
self-report inventory measuring retrospectively experi-
ences of childhood abuse and neglect. It consists of five
subscales: emotional abuse, physical abuse, sexual abuse,
emotional neglect and physical neglect, reflecting there-
fore a broad range of early adverse experiences. There is
an additional 3-item Minimisation/Denial scale aiming
to detect false-negative trauma reports [32]. Participants
are asked to rate the frequency with which they have
shared the reported childhood experiences on a 5-point
Likert scale (1-5). The Childhood Trauma Questionnaire
has been established as a reliable and valid measure of
childhood traumatic experiences [32]. The CTQ has
proved to have high internal reliability with a value
ranging from 0.66 for the physical abuse subscale to
0.92 for the sexual abuse subscale. It has also demon-
strated good test-retest reliability ranging from 0.79 to
0.86 for the five subscales over an average period of four
months.
Health status
The EuroQol [33] is used to describe and evaluate
health-related quality of life. Participants are requested
(i) to rate their own health state of five dimensions
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression), (ii) to rate their current health
status on a thermometer ranging 0-100 and (iii) to pro-
vide some background information on age, education,
qualification, employment etc.
Health service costs
Costs of health and social care will be derived from data
collected on each participant on inpatient/outpatient
care, community and primary care services and the
criminal justice system using the Economic Patient
Questionnaire which includes a Psychiatric and a non-
Psychiatric Hospital Record. The measure of patient
outcome for the primary economic analysis will be qual-
ity adjusted life years (QALYs) gained at 2 years follow-
ing recruitment to the trial. The QALYs will be
estimated as the number of life years multiplied by the
utility of each year of observed survival. The main fra-
mework of analysis will be cost effectiveness analysis
and cost acceptability analysis.
Primary Outcome
Primary outcome is compliance behaviour assessed
using the Voice Compliance Scale (VCS) [13,14].
Secondary outcomes
Secondary outcomes include beliefs about voices’ power,
distress, symptoms and costs. The acceptability of
CTCH and user views about the active ingredients is
explored through semi-structured interviews with a pur-
poseful sample of users at the end of the intervention.
The interview schedule will be piloted and modified as
necessary. In all cases, interviews will be audio taped
and fully transcribed. Interviews and analysis will be car-
ried out concurrently and interviews will continue until
data saturation is complete (approximately 10 users in
each site). Data from semi-structured interviews will be
analysed using a grounded theory approach [34] where
theories are generated from data; this will follow the
methodology of a recent study conducted by one of the
applicants [35].
Predictor variables
History of suicide, self harm and harm to others is col-
lected as part of the baseline assessments. Data about
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using the Childhood Trauma Questionnaire.
Analysis
Power
A sample size of 100 per group will have 84% power to
detect an absolute difference between a proportion who
have acted on their voices of 40% under TAU and 20%
under the CTCH arms using a Pearson chi-square test
with two-tailed significance level of 0.05.
Planned Analyses
The evaluation of the primary outcome will be through
an intention-to-treat (ITT) analysis using a logistic
regression, allowing for centre membership and severity
of command hallucinations at baseline. This will com-
prise a likelihood-based analysis to simultaneously esti-
mate treatment effects at both the 9- and 18-month
follow-up assessments and to allow for missing follow-
up data that are assumed to be Missing at Random
(MAR) in the terminology of Little & Rubin [36]. Analo-
gous ANCOVA methods will be used for the analysis of
the secondary outcomes.
Planned Subgroup Analyses
Predictors of treatment adherence will be investigated
through the use of logistic regression modelling. In line
with the pilot, this will include an analysis of the effect
of ICD-10 classification (schizophrenia vs other psy-
choses) on treatment response. The effect of treatment
on those who received it will be calculated through the
estimation of a Complier-Average Causal Effect (CACE),
using methods similar to those recently described by
Dunn et al [37], including checking the sensitivity of the
estimates to different operational definitions of adher-
ence and assumptions concerning potentially missing
outcome data. This approach will also be extended to
test for and estimate the strength of possible mediating
effects of therapy [38]. In a further exploratory analysis,
predictors of command compliance, including self-harm
and harm to others will also be identified through the
use of logistic regression.
Discussion
Preliminary findings [14] point towards evidence for the
reasonable effectiveness of the CTCH but this large
scale trial will provide more definitive results about the
efficacy of the intervention and the durability of its
effects. This intervention is among the very few that
focus on targeting individuals’ appraisals, behaviour and
affect and not necessarily symptoms; this is also
reflected in the outcome measures used.
If successful, the results will mark a significant break-
through in the evidence base for clinicians and service
users who act on their voices with harmful conse-
quences or are at high risk of doing so.
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